Two Sigma Investments
GILD icon

Two Sigma Investments’s Gilead Sciences GILD Stock Holding History

Two Sigma Investments’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$836K Hold
6,000
– – ﹤0.01% 3396
2025
Q4 		$736K Buy
+6,000
New +$729K ﹤0.01% 3109
2022
Q1 		– Sell
-182,400
Closed -$13.2M – 3296
2021
Q4 		$13.2M Sell
182,400
-5,100
-3% -$351K 0.03% 653
2021
Q3 		$13.1M Sell
187,500
-58,900
-24% -$4.14M 0.03% 643
2021
Q2 		$17M Sell
246,400
-299,400
-55% -$20M 0.04% 558
2021
Q1 		$35.3M Buy
545,800
+279,000
+105% +$18M 0.09% 250
2020
Q4 		$15.5M Sell
266,800
-28,600
-10% -$1.73M 0.04% 445
2020
Q3 		$18.7M Buy
295,400
+186,800
+172% +$13M 0.07% 314
2020
Q2 		$8.36M Buy
108,600
+85,100
+362% +$6.52M 0.04% 448
2020
Q1 		$1.76M Sell
23,500
-13,800
-37% -$954K 0.01% 1033
2019
Q4 		$2.42M Sell
37,300
-187,900
-83% -$12.2M 0.01% 1439
2019
Q3 		$14.3M Buy
225,200
+114,000
+103% +$7.45M 0.05% 442
2019
Q2 		$7.51M Sell
111,200
-133,300
-55% -$8.77M 0.03% 719
2019
Q1 		$15.9M Buy
244,500
+188,500
+337% +$12.5M 0.05% 477
2018
Q4 		$3.5M Buy
56,000
+46,200
+471% +$3.23M 0.01% 965
2018
Q3 		$757K Sell
9,800
-207,200
-95% -$15.6M ﹤0.01% 2179
2018
Q2 		$15.4M Buy
217,000
+122,500
+130% +$8.65M 0.05% 503
2018
Q1 		$7.12M Buy
94,500
+73,600
+352% +$5.85M 0.02% 755
2017
Q4 		$1.5M Sell
20,900
-41,100
-66% -$3.12M ﹤0.01% 1688
2017
Q3 		$5.02M Buy
62,000
+7,400
+14% +$566K 0.02% 801
2017
Q2 		$3.87M Buy
54,600
+30,600
+128% +$2.04M 0.01% 999
2017
Q1 		$1.63M Sell
24,000
-112,300
-82% -$7.9M 0.01% 1581
2016
Q4 		$9.76M Buy
136,300
+85,300
+167% +$6.34M 0.04% 540
2016
Q3 		$4.04M Buy
51,000
+26,000
+104% +$2.11M 0.01% 998
2016
Q2 		$2.09M Sell
25,000
-58,000
-70% -$5.15M 0.01% 1237
2016
Q1 		$7.62M Buy
83,000
+31,000
+60% +$2.8M 0.04% 536
2015
Q4 		$5.26M Buy
52,000
+27,000
+108% +$2.81M 0.03% 650
2015
Q3 		$2.46M Buy
25,000
+7,000
+39% +$777K 0.01% 761
2015
Q2 		$2.11M Buy
18,000
+5,000
+38% +$546K 0.01% 1160
2015
Q1 		$1.28M Buy
+13,000
New +$1.32M 0.01% 1429

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Two Sigma Investments's GILD Position: Q1 2026 in Review

Two Sigma Investments opened a new position in Gilead Sciences (GILD) in Q1 2026: 13,500 shares worth $1.88M. The stake represents ﹤0.01% of the portfolio and ranks #2796 among its holdings. This is a return to the name: Two Sigma Investments previously reported a position in GILD as recently as Q1 2025.

Two Sigma Investments first reported a position in GILD in Q2 2013 and has held it in 45 quarters since. The position peaked at $254M in Q4 2022. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Two Sigma Investments held 13,500 shares of Gilead Sciences worth $1.88M as of Q1 2026.
  • Gilead Sciences was a new Two Sigma Investments position in Q1 2026.
  • Gilead Sciences made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #2796 holding.
  • Two Sigma Investments first reported a position in Gilead Sciences in Q2 2013 and has held it in 45 quarters since.
  • Two Sigma Investments's Gilead Sciences position peaked at $254M in Q4 2022.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.